Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.

MLA

Othman, Tamer A., et al. “Rebound Thrombocytosis Is Associated with Response in AML Patients Treated with Venetoclax and Hypomethylating Agents.” American Journal of Hematology, vol. 96, no. 5, May 2021, pp. E140–43. EBSCOhost, https://doi.org/10.1002/ajh.26117.

APA

Othman, T. A., Mei, M., Zhang, J., Aldoss, I., Stein, A., Forman, S. J., Marcucci, G., & Pullarkat, V. (2021). Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents. American Journal of Hematology, 96(5), E140–E143. https://doi.org/10.1002/ajh.26117

Chicago

Othman, Tamer A., Matthew Mei, Jianying Zhang, Ibrahim Aldoss, Anthony Stein, Stephen J. Forman, Guido Marcucci, and Vinod Pullarkat. 2021. “Rebound Thrombocytosis Is Associated with Response in AML Patients Treated with Venetoclax and Hypomethylating Agents.” American Journal of Hematology 96 (5): E140–43. doi:10.1002/ajh.26117.